After Reaching Milestone, Is Fortress Biotech Inc (NASDAQ:FBIO)’s Short Interest Revealing Something?

May 26, 2018 - By Dolores Ford

Fortress Biotech, Inc. (NASDAQ:FBIO) Logo

The stock of Fortress Biotech Inc (NASDAQ:FBIO) registered a decrease of 23.31% in short interest. FBIO’s total short interest was 815,900 shares in May as published by FINRA. Its down 23.31% from 1.06M shares, reported previously. With 111,400 shares average volume, it will take short sellers 7 days to cover their FBIO’s short positions. The short interest to Fortress Biotech Inc’s float is 2.84%.

The stock increased 10.22% or $0.32 during the last trading session, reaching $3.45. About 699,421 shares traded or 305.56% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 25.00% since May 26, 2017 and is uptrending. It has outperformed by 13.45% the S&P500.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $182.51 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 3 analysts covering Fortress Biotech (NASDAQ:FBIO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 9 analyst reports since December 5, 2017 according to SRatingsIntel. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) has “Buy” rating given on Tuesday, March 27 by H.C. Wainwright. The rating was maintained by H.C. Wainwright on Monday, May 21 with “Buy”. The stock of Fortress Biotech, Inc. (NASDAQ:FBIO) has “Buy” rating given on Tuesday, December 12 by H.C. Wainwright. JMP Securities maintained it with “Buy” rating and $1100 target in Monday, May 21 report. The firm earned “Buy” rating on Friday, March 16 by H.C. Wainwright. H.C. Wainwright maintained the shares of FBIO in report on Tuesday, December 5 with “Buy” rating. As per Tuesday, January 2, the company rating was maintained by H.C. Wainwright. As per Friday, May 11, the company rating was maintained by H.C. Wainwright.

More notable recent Fortress Biotech, Inc. (NASDAQ:FBIO) news were published by: Globenewswire.com which released: “National Holdings Corporation Reports Financial Results for the Fiscal Second Quarter 2018” on May 15, 2018, also Nasdaq.com with their article: “Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights” published on May 10, 2018, Globenewswire.com published: “Fortress Biotech Appoints Michael G. King, Jr. as Entrepreneur in Residence” on May 15, 2018. More interesting news about Fortress Biotech, Inc. (NASDAQ:FBIO) were released by: Nasdaq.com and their article: “Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of …” published on May 21, 2018 as well as Globenewswire.com‘s news article titled: “Mustang Bio Reports First Quarter 2018 Financial Results” with publication date: May 14, 2018.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.